Q-omics provides the consensus-scored LIFR-AS1 profile across patient tissues and cancer cell-line models. LIFR-AS1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LIFR-AS1 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, LIFR-AS1 RNA expression shows 19,310 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, THCA, and TGCT as cancer lineages where LIFR-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIFR-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIFR-AS1 survival associations across molecular data types. LIFR-AS1 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIFR-AS1 RNA expression–survival associations across cancer types. High LIFR-AS1 expression shows unfavorable associations in STAD, but favorable associations in LUAD, KIRC, KIRP, UCS and PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LIFR-AS1 RNA expression.
This table summarizes LIFR-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LIFR-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIFR-AS1 shows lower tumor expression in THCA, KICH, KIRC, LUAD, COAD and UCEC. The THCA box plot shows higher LIFR-AS1 RNA expression in normal versus tumor tissue (log2 FC = −1.872, t-test p < 0.001).
This table shows molecular features associated with LIFR-AS1 in patient tissues and cancer cell lines. In patient samples, LIFR-AS1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
